Bioartificial kidney gets its “living membrane”

Researchers have come one step closer to developing a bioartificial kidney by producing the “living membrane” portion of the kidney. The latest in the development is set to be presented at American Society of Nephrology (ASN) Kidney Week 2016.

For the millions of patients suffering from renal failure, the only approach to treatment is waiting on the donor list while undergoing dialysis. In an effort to expand methods of treatment, researchers have begun to develop a bioartificial kidney. Building a kidney is easier said than done, though, and development takes innovation, investment and time.

Lead by Dimitrios Stamatialis, PhD, of the Netherlands' University of Twente, and Roos Masereeuw, PhD, of the University of Utrecht, also in the Netherlands, the team of researchers have developed a major piece to the bioartificial kidney puzzle. The development of the “living membrane," the cell layer of the kidney on an artificial membrane that transports molecules. Using conditionally immortalized human renal proximal tubular epithelial cells (ciPTEC) on polyethersulfone-based hollow fiber membranes, the membrane functions as the “living membrane” of the kidney.

"This study shows the successful development of a living membrane consisting of a reproducible ciPTEC monolayer on hollow fiber membranes, an important step towards the development of a bioartificial kidney device," said Stamatialis. "The strategies and methods of this work could be relevant to the development of other bioartificial organs, such as a bioartificial liver or bioartificial pancreas, and organs on chips—such as a kidney on chip, a lung on chip or a liver on chip."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.